{"id":"vancomycin-model-based-dosing-regimen","safety":{"commonSideEffects":[{"rate":"5-25","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"1-5","effect":"Ototoxicity (hearing loss)"},{"rate":"10-30","effect":"Red man syndrome (flushing, pruritus, erythema)"},{"rate":"5-15","effect":"Phlebitis at infusion site"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking transglycosylation and transpeptidation reactions essential for cell wall integrity. This leads to cell wall weakening and bacterial cell lysis. The model-based dosing regimen optimizes pharmacokinetic/pharmacodynamic (PK/PD) parameters to achieve target drug exposures that maximize bacterial killing while minimizing toxicity.","oneSentence":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:24.714Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious infections caused by susceptible Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus)"},{"name":"Clostridium difficile-associated diarrhea"},{"name":"Endocarditis"},{"name":"Meningitis"}]},"trialDetails":[{"nctId":"NCT06161870","phase":"PHASE4","title":"Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model","status":"RECRUITING","sponsor":"Central South University","startDate":"2021-01-01","conditions":"Severe Infection","enrollment":112},{"nctId":"NCT04044703","phase":"PHASE4","title":"Improving Dosing of Vancomycin in Young Infants With Infections","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2019-08-30","conditions":"Sepsis, Infection, Bacteremia","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin - model-based dosing regimen","genericName":"Vancomycin - model-based dosing regimen","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Serious infections caused by susceptible Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus), Clostridium difficile-associated diarrhea, Endocarditis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}